Femasys will present its fertility treatment and diagnostic portfolio at the ASRM 2026 Scientific Congress & Expo, highlighting its efforts to expand adoption across OB/GYN practices and reproductive endocrinology clinics.
Key Investor Takeaways
- Femasys (NASDAQ:FEMY) will exhibit at the ASRM 2026 Scientific Congress & Expo in Baltimore from October 24–28.
- The company will showcase FemaSeed Intratubal Insemination and FemVue, targeting healthcare providers involved in fertility evaluation and treatment.
- Expansion into OB/GYN practices represents a key component of Femasys’ commercialization strategy, complementing its relationships with reproductive endocrinologists.
- The event provides an opportunity to engage potential clinical users and discuss patient selection, clinical evidence and integration into existing medical practices.
- Femasys continues to advance its separate FemBloc permanent birth control program through the ongoing FINALE pivotal trial.
Why FEMY Stock Is in Focus
Femasys has confirmed its participation in the American Society for Reproductive Medicine’s 2026 Scientific Congress & Expo, where it will promote its fertility portfolio to reproductive medicine specialists.
The company will exhibit at booth #513 during the five-day conference at the Baltimore Convention Center.
Its presentation will focus on FemaSeed, an intratubal insemination treatment designed to provide an additional fertility option for appropriately selected patients, and FemVue, an in-office diagnostic product used to evaluate fallopian tubes.
Femasys is positioning these products within a connected fertility care pathway involving obstetrician-gynecologists (OB/GYNs) and reproductive endocrinologists and infertility specialists (REIs).
The company is expanding its commercial reach into OB/GYN practices while maintaining relationships with specialist fertility centers.
According to management, FemaSeed is intended to give reproductive specialists another treatment option when assessing patients’ fertility needs, including decisions about whether to proceed to in vitro fertilization (IVF).
Conference discussions will cover clinical data, patient selection and how the products can be incorporated into existing healthcare workflows.
The announcement does not include new clinical trial results, product sales figures or commercial agreements.
Why This Matters for Investors
Femasys’ participation in ASRM 2026 supports its ongoing efforts to increase awareness and adoption of its fertility technologies among healthcare professionals.
For a medical technology company focused on commercialization, engagement with physicians and fertility specialists may be important in establishing product familiarity and encouraging integration into routine clinical practice.
The expansion into OB/GYN practices could broaden the company’s potential customer base by introducing fertility evaluation and treatment options earlier in the patient care process.
At the same time, maintaining relationships with reproductive endocrinologists allows Femasys to position its products as complementary to established specialist fertility services rather than replacements for them.
This approach may create opportunities for broader utilization of FemaSeed and FemVue across different stages of fertility care.
The pairing of a diagnostic product with a treatment option also provides Femasys with an opportunity to promote multiple products within the same clinical workflow.
However, conference participation does not establish increased product adoption or future revenue growth.
The announcement provides no measurable commercial targets or financial guidance, meaning the immediate significance is primarily related to marketing activity and physician engagement.
For investors, the more substantial indicator of progress will be whether these commercialization initiatives translate into greater clinical utilization and sustained product demand.
What to Watch Next
The ASRM conference, scheduled for October 24–28, represents the next opportunity for Femasys to engage reproductive medicine professionals and communicate its fertility portfolio strategy.
Investors should monitor subsequent updates on FemaSeed adoption, expansion into OB/GYN practices and the development of commercial relationships in the United States and international markets.
Progress involving FemBloc will also remain relevant to the company’s broader development pipeline.
The non-surgical permanent birth control product is undergoing the FINALE pivotal trial as Femasys works toward U.S. FDA approval.
FemBloc received regulatory approvals in Europe, the United Kingdom and New Zealand in 2025, providing a basis for commercialization through selected international partnerships.
For Femasys, the central question is whether expanded physician engagement and its developing distribution strategy can translate into measurable commercial growth while its longer-term product pipeline advances.